Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Perrigo Company    PRGO

PERRIGO COMPANY (PRGO)
Mes dernières consult.
Most popular
  Report  
 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles
Financials (USD)
Sales 2018 5 033 M
EBIT 2018 1 058 M
Net income 2018 400 M
Debt 2018 2 251 M
Yield 2018 0,97%
Sales 2019 5 179 M
EBIT 2019 1 113 M
Net income 2019 479 M
Debt 2019 1 684 M
Yield 2019 0,94%
P/E ratio 2018 25,33
P/E ratio 2019 20,27
EV / Sales2018 2,53x
EV / Sales2019 2,35x
Capitalization 10 504 M
More Financials
Company
Perrigo Co. Plc is a healthcare company, which engages in the production of over-the-counter consumer goods and specialty pharmaceutical products.It operates through the following segments: Consumer Healthcare Americas, Consumer Healthcare International, and Prescription Pharmaceuticals.The... 
Sector
Pharmaceuticals
Calendar
08/09Earnings Release
More about the company
Surperformance© ratings of Perrigo Company
Trading Rating : Investor Rating :
More Ratings
Latest news on PERRIGO COMPANY
06/08PERRIGO COMPANY : Report
CO
05/31PERRIGO : Confirms Patent Challenge For Generic Version Of Sernivo® Spray, 0.05%
AQ
05/31PERRIGO COMPANY PLC : Ex-dividend day for
FA
05/30PERRIGO : to Present at the Jefferies 2018 Healthcare Conference
PR
05/25PERRIGO : Confirms First To File Patent Challenge For Generic Version Of Ultrava..
AQ
05/25PERRIGO : Expects Complete Response Letter On Generic Version Of ProAir®
AQ
05/24PERRIGO : Confirms Patent Challenge For Generic Version Of Sernivo® Spray, 0.05%
PR
05/18PERRIGO : Confirms First To File Patent Challenge for Generic Version of Ultrava..
AQ
05/17PERRIGO COMPANY : Report
CO
05/14PERRIGO : Confirms First To File Patent Challenge For Generic Version Of Ultrava..
PR
More news
Sector news : Pharmaceuticals - NEC
06/22Federal Judge Gives Lilly Win on Alimta Regimen Patent
DJ
06/22JOHNSON & JOHNSON : Remakes Top Leadership -- Update
DJ
06/22JOHNSON & JOHNSON : Worldwide Chairman Peterson to Retire
DJ
06/22SHIRE PLC SHIRE PLC : Rule 2.9 Announcement
DJ
06/22Roche to Appoint James Sabry as Head of Partnering
DJ
More sector news : Pharmaceuticals - NEC
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 18
Average target price 89,8 $
Spread / Average Target 19%
EPS Revisions
Managers
NameTitle
Uwe Röhrhoff President, Chief Executive Officer & Director
Rolf Allan Classon Chairman
Ronald Janish Executive VP-Global Operations and Supply Chain
Ron L. Winowiecki Chief Financial Officer
Thomas Farrington Chief Information Officer & Executive VP
Sector and Competitors
1st jan.Capitalization (M$)
PERRIGO COMPANY10 504
JOHNSON & JOHNSON-12.27%327 330
PFIZER0.00%213 275
NOVARTIS-10.87%189 575
ROCHE HOLDING LTD.-12.58%188 417
MERCK AND COMPANY8.90%164 862